Renalytix AI plc develops artificial intelligence (AI) enabled clinical decision support solutions for kidney disease. It is developing KidneyIntelX, an AI-enabled, clinical-laboratory based solution that supports physician decision making by improving identification, prediction, and risk stratification of patients with kidney disease. The company is based in Cardiff, the United Kingdom. Renalytix AI plc (AIM:RENX) operates independently of EKF Diagnostics Holdings plc as of November 2, 2018.